You are here

BCRF Grantee Since


Donor Recognition

The Hamptons Paddle & Party for Pink Award

Robert J. Schneider, PhD

Associate Dean, Office of Therapeutic Alliances
Associate Director, NYU Cancer Institute
Co-Director, Breast Cancer and Translational Cancer Research
Albert B. Sabin Professor of Molecular Pathogenesis
NYU School of Medicine
New York, New York

Current Research

Co-Investigator: Silvia Formenti, MD, NYU School of Medicine, New York

Dr. Schneider and his team are focusing on the understanding of the role of selective protein synthesis in the regulation, survival and resistance to treatment of breast cancer cells that are thought to be responsible for breast cancer metastasis and recurrence. The studies conducted in the past year are developing a novel approach pioneered arch that targets an area of gene regulation not previously exploited to more effectively treat advanced and metastatic breast cancer.

Studies to be conducted over the coming year will focus on investigating how inhibition of the translation initiation factor eIF4G1 or catalytic inhibition of the inhibitors mTORC1/2 generate such remarkable synergy in treatment response and tumor control, particularly significantly impairing metastasis. Dr. Schneider’s team will develop an understanding for the pharmacologic use of mTORC1/2 inhibitors in the preclinical setting, as they complete a Phase 1B single agent clinical trial and use this information to develop a Phase II combinatorial drug trial.

Mid-Year Summary

One of the major goals of breast cancer treatment is to more effectively treat metastatic disease, particularly breast cancer that has spread to the brain, for which there are no curative treatments. Dr. Schneider’s research is directed to developing inhibitors of metastatic breast cancer by targeting the specific changes in the protein synthesis machinery of breast cancer cells controlled by the kinase mTOR. Based on his team’s research conducted over the past year, they have shown that hyper-activated mTOR and components of the protein synthesis machinery are important for the spread and survival of metastatic breast cancer cells. The researchers have now developed clinical trials to test novel experimental inhibitors of mTOR for the treatment of metastatic breast cancer, particularly breast cancer that has metastasized to the brain.


Robert Schneider, PhD, is the Albert Sabin Professor of Molecular Pathogenesis at the NYU School of Medicine; an Associate Director of the NCI-designated NYU Cancer Institute, Director of Translational Research, Co-Director of the NYU Breast Cancer Program and a Professor of Radiation Oncology. He is the author of more than 130 peer reviewed publications in oncology. He conducts research directed to the development, progression and metastasis of breast cancer and the interplay of the inflammatory response. His research effort concerns the molecular and genetic understanding of advanced and metastatic breast cancers and the development of new treatment strategies and therapeutics for metastatic disease.

Dr. Schneider performs basic, translational and clinical research on the molecular basis of locally advanced, metastatic and inflammatory breast cancers and the development of new therapeutics from these findings. He has received numerous awards and prizes in recognition of his achievements, including: the 2011 Distinguished Alumnus Award & Commencement address, University of Delaware; the 2010 Judah Folkman Memorial lecture, Chemotherapy Foundation; 2010 Keynote speaker for FASEB, AACR, RNA Society conferences; the Director of the International Consortium for Inflammatory Breast Cancer; the 2009 Royal Society of Medicine address; 2005-2011, Member of the Department of Defense Senior Advisory Council on Breast Cancer; 2005 Commencement address: Miami University, Ohio, School of Arts & Sciences graduation; 2005 Department of Defense Center of Excellence in breast cancer (with Dr. Silvia Formenti); 2005 Distinguished Scientist Award, Purdue University; the 2012 Susan E. Donelan Hope for the Future Award for breast cancer research, Dana Farber Cancer Institute.

Dr. Schneider is a member of the American Association for Cancer Researchers, the American Society for Therapeutic Radiation Oncology (ASTRO), the American Society of Clinical Oncology, the Radiation Research Society (RRS), and the American Society for Microbiology (ASM) among others. He serves on the Editorial Boards of Cancer Research, Molecular and Cellular Biology and Translation. Dr. Schneider is a founding scientist of five biotechnology/small pharmaceutical companies: ImClone Systems, PTC Therapeutics Inc., Canji, Gencell (Paris), and Charterhouse Pharmaceuticals (London).